Participants
psychotic disorder, psychedelic drug, SD, psychiatric disorder, diabetes
DIABETES
Eleven healthy participants (seven male, four female, mean age ± SD = 37.09 ± 8.93 years, range = 26–51 years) took part in this study. Participants were recruited via word of mouth. Exclusion criteria for study participation were age <18, current or previously diagnosed psychiatric disorder, family history of psychotic disorder, a medically significant condition which rendered them unsuitable for the study (e.g., heart condition, diabetes), an abnormal physical exam, electrocardiogram, or blood test, no prior experience with a psychedelic drug, previous adverse response to a hallucinogenic drug, blood or needle phobia, a positive pregnancy test at screening or during the study, and excessive use of alcohol or other drugs (>40 units per week). Participants were asked to not consume any alcoholic drinks 48 h before each study visit, and to not consume any illicit drugs 2 weeks before their first study visit until 2 weeks after their last study visit. Drug of abuse tests and pregnancy tests (where applicable) were performed before each dosing visit. All subjects gave written informed consent in accordance with the Declaration of Helsinki.